Sun Y, Guan X, Wang H, et al. - Whether oral α‐lipoic acid (ALA: an antioxidative agent) in combination with NB‐UVB phototherapy has efficacy and safety in the treatment of non‐segmental stable vitiligo, was determined in this prospective, multi‐center, parallel controlled, double‐blind randomized clinical trial. This analysis included 133 patients who were randomly assigned to an oral ALA group or placebo group at a dose of 300 mg daily for 6 months. All patients were treated with NB‐UVB phototherapy 3 times weekly. Experts assessed re‐pigmentation rate using 4‐point grading scale of improvement: > 98%, 50%‐98%, 10%‐49%, < 10%. According to the findings, ALA did not demonstrate additional benefit to NB‐UVB therapy in the management of non‐segmental stable vitiligo.